Study ID | Intervention(s) and comparator(s) | Participants included in analysis (N) | Participants with at least one hypoglycaemic episode (N) | Participants with at least one hypoglycaemic episode (%) | Participants with at least one severe/serious hypoglycaemic episode (N) | Participants with at least one severe/serious hypoglycaemic episode (%) |
Duncan 2018 | I: hyperinsulinaemic normoglycaemia | 226* | 24* | 10.6* | 1* | 0.4* |
C: standard therapy | 249* | 1* | 0.4* | 1* | 0.4* | |
Wallia 2017 | I: intensive (140) | 23* | 11* | 47.8* | 2* | 8.7* |
C: moderate (180) | 26* | 1* | 3.9* | 0* | 0* | |
Wahby 2016 | I: tight glycaemic control | 67 | 3 | 4.5 | — | — |
C: conventional moderate glycaemic control | 68 | 1 | 1.5 | — | — | |
Parekh 2016 | I: moderately intense control | 30 | 0 | 0 | 0 | 0 |
C: standard glucose control | 30 | 0 | 0 | 0 | 0 | |
Yuan 2015 | I: intensive glycaemic management | 106 | — | — | 8 | 7.5 |
C: conventional glycaemic management | 106 | — | — | 1 | 0.9 | |
Umpierrez 2015 | I: intensive group | 77* | 7* | 9* | 0* | 0* |
C: conservative control | 75* | 4* | 5* | 0* | 0* | |
Abdelmalak 2013 | I: intensive glucose management | 54* | 0* | 0* | 1* | 1.9* |
C: conventional glucose management | 49* | 0* | 0* | 0* | 0* | |
Hermayer 2012 | I: intensive glycaemic control | 44 | — | — | 7 | 16 |
C: standard glycaemic control | 49 | — | — | 2 | 4 | |
Desai 2012 | I: strict blood glucose control | 37* | 18* | 48,6* | 1* | 2.7* |
C: liberal blood glucose control | 44* | 15* | 34.1* | 0* | 0* | |
Lazar 2011 | I: aggressive glucose control | 40 | — | — | 30 | 75 |
C: moderate glucose control | 42 | — | — | 4 | 9.52 | |
Cao 2010 | I: intensive insulin therapy | 92 | — | — | 6 | 6.5 |
C: conventional insulin therapy | 87 | — | — | 1 | 1.1 | |
Glucontrol 2009 | I: intensive insulin treatment | 55* | — | — | 3* | 5,5* |
C: intermediate glucose control | 69* | — | — | 1* | 1.4* | |
NICE SUGAR 2009 | I: intensive insulin therapy | 213* | ‐ | ‐ | 14* | 6.6* |
C: conventional insulin therapy | 208* | ‐ | ‐ | 1* | 0.5 | |
Subramaniam 2009 | I: continuous insulin infusion | 62* | 8* | 12.9* | 0* | 0* |
C: standard intermittent sliding‐scale insulin bolus | 64* | 2* | 3.1* | 0* | 0* | |
Chan 2009 | I: intensive insulin therapy | 10* | 0* | 0* | — | — |
C: conventional insulin therapy | 22* | 0* | 0* | — | — | |
De La Rosa 2008 | I: intensive insulin therapy | 11* | — | — | 0* | 0* |
C: conventional insulin therapy | 2* | — | — | 1* | 50* | |
Gandhi 2007 | I: intensive insulin therapy | 37 | 1 | 3 | — | — |
C: conventional insulin therapy | 36 | 6 | 16.6 | — | — | |
Li 2006 | I: continuous insulin infusion | 51 | — | — | — | — |
C: glucometer‐guided insulin | 42 | — | — | — | — | |
Lazar 2004 | I: tight glycaemic control with GIK | 72 | — | — | — | — |
C: standard therapy | 69 | — | — | — | — | |
Rassias 1999 | I: aggressive insulin therapy | 13 | — | — | — | — |
C: standard insulin therapy | 13 | — | — | — | — | |
—: denotes not reported *data provided by study authors (patients with diabetes). adata from total study population. C: comparator; I: intervention;GIK: glucose‐insulin‐potassium. |